Treatment of severe pneumonia - Community-acquired and "early onset" nosocomial;Therapiekonzepte bei schweren pneumonien - Ambulant erworben und nosokomial "early onset"

Medizinische Klinik

Volumn 99, Issue 7, 2004, Pages 362-371

  Höffken, Gert ^a   Halank, Michael ^a   Gillissen, Adrian ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Robert Koch Klinik   (Germany)

Author keywords

Community acquired pneumonia; Elderly patients; Hospitalized patients; Treatment regimen; Underlying diseases

Indexed keywords

AMINOPENICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; ERTAPENEM; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGED; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DISEASE SEVERITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG INDICATION; GERIATRIC CARE; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LENGTH OF STAY; PNEUMONIA; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS);

EID: 3242688886     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-004-1055-0     Document Type: Review

References (120)

1. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003;47:1643-6.
2. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies - a consensus statement. Am J Respir Crit Care Med 1995;153:1711-25.
3. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
4. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa. Arch Intern Med 2002;162:1849-58.
5. Bartlett JG, Dowell SF, Mandell LA, et al. Guidelines from the Infectious Diseases Society of America: practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
6. Bartlett JG, Mundy LM. Current concepts: community-acquired pneumonia. N Engl J Med 1995;333:1618-24.
7. Bauerfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin. J Antimicrob Chemother 1997;40:639-51.
8. Bodmann K-F, Lorenz J, Bauer TT, et al. Nosokomiale Pneumonie: Prävention, Diagnostik und Therapie. Ein Konsensuspapier der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG) und der Deutschen Gesellschaft für Pneumologie (DGP) unter Mitarbeit von Experten der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin (DGAI). Chemother J 2003;12:33-44.
9. Bou G, Oliver A, Ojeda M, et al. Molecular characterization of FOX-4, a new AmpC-type plasmid-mediated β-lactamase from an Escherichia coli strain isolated in Spain. Antimicrob Agents Chemother 2000;44:2549-53.
10. British Thoracic Society. Guidelines for the management of community acquired pneumonia in adults. Thorax 2001;56:Suppl 4:1-64.
11. Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003;123:1503-11.
12. Cao V, Lambert T, Nhu DQ, et al. Distribution of extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother 2002;46:3739-43.
13. Carbon C, Ariza H, Rabie WJ, et al. Comparative study of levofloxacin and amoxicillin/clavulanic acid in adults with mild to moderate community-acquired pneumonia. Clin Microb Infect 1999;5:724-32.
14. Centers for Disease Control and Prevention. Pneumonia and influenza death rates: United States, 1979-1994. MMWR Morb Mort Wkly Rep 1995;44:535-7.
15. Cunha BA. Ertapenem: a review of its microbiologic, pharmacokinetic and clinical aspects. Drugs Today 2002;38:195-213.
16. Dahmash NS, Chowdhury MNH. Re-evaluation of pneumonia requiring admission to an intensive care unit: a prospective study. Thorax 1994;49:71-6.
17. Daley J, Jencks S, Draper D, et al. Predicting hospital-associated mortality for medical patients. JAMA 1988;260:3617-24.
18. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003;22:203-21.
19. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
20. Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001;110:451-7.
21. Dean NC, Suchyta MR, Bateman KA, et al. Implementation of admission decision support for community-acquired pneumonia. Chest 2000;117:1368-77.
22. Doem GV, Pfaller MA, Kugler F, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 1998;27:764-70.
23. Drinka PJ, Gauerke C, Voeks S, et al. Pneumonia in a nursing home. J Gen Intern Med 1994;9:650-2.
24. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest 1998;113:1542-8.
25. Ewig S, Reinert RR, Wiedemann B, et al. Antibiotika-Resistenz bei Erregem ambulant erworbener Atemwegsinfektionen. Chemother J 2002;11:12-26.
26. Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-8.
27. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999;159:1835-42.
28. Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8.
29. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implication for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990;69:307-16.
30. Farr BM, Sloman AJ, Fish MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991;115:428-36.
31. Feik A. Pneumonia in elderly: special diagnostic and therapeutic considerations. Med Clin North Am 1994;78:1015-33.
32. Fein AM. Pneumonia in the elderly: overview of diagnostic and therapeutic approaches. Clin Infect Dis 1999;28:726-9.
33. Feldman C, Ross S, Mahomed AG, et al. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy. Respir Med 1995;89:187-92.
34. Finch R, Schuermann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746-54.
35. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
36. Fine MJ, Hanusa BH, Lave JR, et al. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia. J Gen Intern Med 1995;10:359-68.
37. Fine MJ, Smith MA, Carson CA. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996;275:134-41.
38. Friedland I, Isaacs R, Moll J, et al. Health-care associated pneumonia acquired outside the ICU: results of a randomized, double-blind study comparing ertapenem and cefepime. Presented at the ECCMID, Glasgow 2003.poster P788.
39. Friedland IR, Harm S, Stinson L, et al. Pseudomonas aeruginosa resistance to imipenem (IMI), ertapenem (ETP), and other antibiotics: results of a multicenter ICU study. Presented at the ICAAC, Chicago 2001.abstract E-805.
40. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am J Med 1985;78:32S-7S.
41. Georges H, Leroy O, Vandenbussche C, et al. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999;25:198-206.
42. Gilbert K, Fine MJ. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect 1994;9:140-52.
43. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-72.
44. Goldstein EJC, Citron DM, Merriam CV, et al. Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2000;44:2389-94.
45. Gordon GS, Throop D, Berberian L, et al. Validation of the therapeutic recommendations of the American Thoracic Society (ATS) guidelines for community-acquired pneumonia in hospitalized patients. Chest 1996;110:55S.
46. Hak E, Nordin J, Mullooly J, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002;35:370-7.
47. Hasley PB, Albaum MN, Li YH, et al. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med 1996;156:2206-12.
48. Hedlund JU, Ortqvist AB, Kalin ME, et al. Factors of importance for the long-term prognosis after hospital-treated pneumonia. Thorax 1993;48:785-9.
49. Ho PL, Tse WS, Tsang KWT, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae - a case control study. Clin Infect Dis 2001;32:701-7.
50. Hoe LK, Keang LT. Hospitalized low-risk community-acquired pneumonia: outcome and potential for costsavings. Respirology 1999;4:307-9.
51. Höffken G, Meyer HP, Winter J, et al., for the CAP1 Study Group. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001;95:553-64.
52. Höffken G, Steinhoff D, Lode H, et al. Ätiologie von ambulant erworbenen Pneumonien bei älteren Menschen. Chemother J 1995;4:Suppl 7:13-9.
53. Homer J, Alberts MJ, Davison DV, et al. Swallowing in Alzheimer's disease. Alzheimer Dis Assoc Disord 1994;8:177-89.
54. Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 Western states: 1993, 1995, and 1997. Chest 2001;119:1420-6.
55. Houston MS, Silverstein MD, Suman VJ. Risk factors for 30-day mortality in elderly patients with lower respiratory tract infection. Arch Intern Med 1997;157:2190-5.
56. Hubmayr RD. Statement of the 4th International Consensus Conference in Critical Care on ICU-Acquired Pneumonia, Chicago, IL, May 2002. Intensive Care Med 2002;28:1521-36.
57. Huppertz K, Wiedemann B, GENARS-Projektgruppe. GENARS-Resistenzstatistik. Chemother J 2002;3:102-3.
58. Ibrahim EH, Ward S, Sherman G, et al. A comparative analysis of patients with early-onset versus late-onset pneumonia in the ICU. Chest 2000;117:1434-42.
59. Isaacs R, Teppler H, Friedland I, et al. Ertapenem (ETP) for treatment of bacteremia. Presented at the ICAAC, San Diego 2002.abstract L-380.
60. Jones RN. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. J Chemother 2001;13:363-76.
61. Joshi M, Bernstein J, Solomkin J, et al. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacinin/tazobactam Nosocomial Pneumonia Study Group J Antimicrob Chemother 1999;43:389-97.
62. Kauppinen MT, Saikku P, Kujala P, et al. Clinical picture of Clamydia pneumoniae requiring hospital treatment: a comparison between clamydial and pneumococcal pneumonia. Thorax 1996;51:185-9.
63. Keeler EB, Kahn KL, Draper D, et al. Changes in sickness at admission following the introduction of the prospective payment system. JAMA 1990;264:1962-8.
64. Kikuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration of elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994;150:251-3.
65. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994;96:313-20.
66. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcome implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-20.
67. Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus: pneumonia. Infect Dis Clin North Am 1995;9:65-96.
68. Kresken M, Hafner D, und die Studiengruppe. Resistenzsituation bei Idinisch wichtigen Infektionserregern gegenüber Chemotherapeutika in Mitteleuropa. Chemother J 2000;9:51-86.
69. Leroy O, Santre C, Beuscart C. A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU. Intensive Care Med 1995;21:24-31.
70. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996;51:179-84.
71. Lim WS, van der Eerden MM, Laing RB, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
72. Livermore DM, Carter MW, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45:1860-7.
73. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-85.
74. Mandell LA, Niederman M, The Canadian Community Acquired Pneumonia Consensus Conference Report Group. Antibacterial treatment of community acquired pneumonia in adults: a conference report. Can J Infect Dis 1993;4:25-8.
75. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994;18:501-15.
76. Marrie TJ, Blanchard W. A comparison of nursing home-acquired pneumonia and nursing home patients without pneumonia. J Am Geriatr Soc 1997;45:50-5.
77. Marrie TJ, Durant H. Positive response to any of seven intradermal antigens predicts favorable outcome in patients hospitalized with community-acquired pneumonia. Clin Invest Med 1988;11:10-5.
78. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000;283:749-55.
79. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolicle to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-95.
80. Martínez-Martínez L, Conejo MC, Pascual A, et al. Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal β-lactamase and showing altered porin profiles. Antimicrob Agents Chemother 2000;44:2534-6.
81. Mckean MC. Evidence based medicine: review of BTS guidelines for the management of community acquired pneumonia in adults. J Infect 2002;45:213-8.
82. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4.
83. Moland ES, Thomson KS. In vitro activity of MK-0826 against 253 well characterized strains of Enterobacteriaceae which produce ESBLs and/or AmpC β-lactamases. Presented at the ICAAC, Toronto 2000.abstract 382.
84. Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995;152:1309-15.
85. Neill AM, Martin IR, Weir R, et al. Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51:1010-6.
86. Niederman MS, McCombs JI, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37.
87. Olsen KM, McNabb JC, Fey PD, et al. In vitro activities of MK-0826 and parenteral β-lactam antimicrobials against clinical isolates of ESBL-producing Klebsiella pneumoniae and in an isogenic host. Presented at the ICAAC, Chicago2001.abstract E-807.
88. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, et al. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002;34:1076-83.
89. Ortqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome, and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990;3:1105-13.
90. Overbye KM, Kong L, Mordekhay D, et al. Activity of MK-0826 against clinical strains of cephalosporin resistant Enterobacteriaceae, including strains bearing extended spectrum β-lactamases (ESBL). Presented at the ICAAC, Toronto 2000. abstract 380.
91. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
92. Pankuch GA, Davies TA, Jacobs MR, et al. Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Antimicrob Agents Chemother 2002;46:42-6.
93. Paterson DL, Ko WC, Gottberg A von, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum betalactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
94. Positionspapier. Impfung gegen Pneumokokken-Erkrankungen. Chemother J 2002;11:117-21.
95. Rahal JJ. Extended-spectrum β-lactamases: how big is the problem? Clin Microbiol Infect 2000;6:Suppl 2:2-6.
96. Reinert RR, Al-Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002;49:61-8.
97. Reinert RR, Lütticken R, Briefs C, et al. Antibiotic resistance of Streptococcus pyogenes and Streptococcus pneumoniae strains isolated from RTI of outpatients in Germany, 2000-2001. Presented at the ICAAC, Chicago 2001.poster C2-693.
98. Rello J, Rodriguez R, Jubert P, et al. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Clin Infect Dis 1996;23:723-8.
99. Riquelme R, Torres A, el-Ebiary M, et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996;154:1450-5.
100. Riquelme R, Torres A, el-Ebiary M, et al. Community-acquired pneumonia in the elderly: clinical and nutritional aspects. Am J Respir Crit Care Med 1997;156:1908-14.
101. Ross JJ, Worthington MG, Gorbach SL. Resistance of levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-7.
102. Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gramnegative infections. Antibiotic Study Group. Clin Infect Dis 1995;20:1217-28.
103. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999;160:397-405.
104. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia: risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999;160:923-9.
105. Schleupner CJ, Cobb DK. A study of the etiologies and treatment of nosocomial pneumonia in a community-base teaching hospital. Infect Control Hosp Epidemiol 1992;13:17SS-29SS.
106. Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections. Chest 1999;115:462-74.
107. Starczewski AR, Allen SC, Vargas E, et al. Clinical prognostic indices of fatality in elderly patients admitted to hospital with acute pneumonia. Age Ageing 1988;17:181-6.
108. Thomson KS, Moland ES, Black JA, et al. Standard and high inoculum MICs of MK-0826 in tests with ESBL, plasmid-mediated AmpC, and multiple β-lactamase-producing Enterobacteriaceae. Presented at the ICAAC, Toronto 2000.abstract 383.
109. Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-8.
110. Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001;184:794-8.
111. Venkatesan P, Gladman J, MacFarlane JT, et al. A hospital study of community-acquired pneumonia in the elderly. Thorax 1990;45:254-8.
112. Vogel F, Naber KG, Scholz H, et al. Empfehlungen einer Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Rationale Therapie bakterieller Atemwegsinfektionen. Chemother J 2000;1:3-23.
113. Vogel F, Naber KG, Wacha H et al. und eine Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Parenterale Antibiotika bei Erwachsenen. Chemother J 1999;8:2-49.
114. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42.
115. Welte T, Klaute T, Piecyk A. Ambulant und nosokomial erworbene Pneumomen. Refresher Pneumologie, Bd 1. Stuttgart: Thieme, 2003:1-24.
116. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003;25:485-506.
117. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J 2002;20:Suppl 36:20s-7s.
118. Woodhead MA, MacFarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;1:671-4.
119. Woods G, Isaacs R, McCarrol K, et al. Utility of ertapenem for community-acquired pneumonia (CAP) in the elderly. Presented at the ICAAC, San Diego 2002.poster L371.
120. Wortman GW, Bennett SP. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae. Clin Infect Dis 1999;29:1599-600.